BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) — Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, announced today that on December 31, 2024, the company granted stock awards to one new employee, pursuant to a plan Company Incentive Stock Incentive for 2024, as incentive material for such new employee who enters employment with the Company in accordance with the Nasdaq Listing Rule 5635(c)(4).
The employee received a total of 5,330 restricted stock units (RSUs). RSUs will vest in equal annual installments on the first four-year anniversary of January 1, 2025, subject to such employee's continued service with the Company on each vesting date.
About Verve Treatments
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic administration to single-course gene editing drugs. The company's flagship programs VERVE-101, VERVE-102, and VERVE-201 target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), the root cause of atherosclerotic cardiovascular disease. (ASCVD). . VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially to treat heterozygous familial hypercholesterolemia (HeFH) and eventually to treat patients with established ASCVD who continue to be affected by elevated LDL-C levels. . VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed to treat treatment-resistant hypercholesterolemia, in which patients continue to have high LDL-C despite treatment with maximally tolerated standard-of-care therapies, and familial hypercholesterolemia. Homologous (HoFH). For more information, please visit www.VerveTx.com.
Contact the investor
Jane Robinson
Verve Therapeutics Inc
jrobinson@vervetx.com
Media communication
Ashlea Kosikovsky
1AB
ashlea@1abmedia.com
Source: Verve Treatments
